Cancer genetics. Coordinator: de Biase

The group carries out its research in the field of solid tumors, whose molecular characteristics are analyzed in ex vivo samples using "high-throughput" methods, to search for new diagnostic, prognostic, or predictive biomarkers

Research themes

Molecular characterization of other solid tumors.

Search for diagnostic / prognostic / predictive markers for the characterization of the following solid tumors: thyroid neoplasia, brain tumors, gynecological tuors, breast cancers, colorectal cancers, pancreatic cancers, melanomas, lung cancers, endocrine cancers, hepatocarcinomas

Development of molecular analysis methods for solid tumors.

Development of laboratory-developed panels for massive parallel sequencing of solid tumors.

Cancer immunology

Cancer immunology and resistance to immunotherapies. Study of tumor progression and therapy resistance mechanisms in lung and breast cancer. Study of the reuse of waste from the agri-food chain as a supplement for cell cultures.

Internship projects

PhD programme in “Cellular and molecular biology ” (Research Area: Molecular characterization of solid tumors)

First and second cycle degrees:

Characterization of solid tumors: Dario de Biase

Cancer immunology: Arianna Palladini

Main publications

  • Next-Generation Sequencing Panel for 1p/19q Codeletion and IDH1-IDH2 Mutational Analysis Uncovers Mistaken Overdiagnoses of 1p/19q Codeletion by FISH. Journal of Molecular Diagnostics, 2021, 23(9):1185-1194. doi: 10.1016/j.jmoldx.2021.06.004
  • ARID1A and CTNNB1/β-catenin molecular status affects the clinicopathologic features and prognosis of endometrial carcinoma: Implications for an improved surrogate molecular classification. Cancers, 2021, 13(5): 1-22.
  • MiR-196B-5P and miR-200B-3P are differentially expressed in medulloblastomas of adults and children. Diagnostics, 2021, 10(51).
  • Molecular diagnostic of solid tumor using a next generation sequencing custom-designed multi-gene panel. Diagnostics, 2020, 10(4), 250.
  • Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4. Cancer biomarkers, 2018, 21(2):323-334. doi: 10.3233/CBM-170464